Format

Send to

Choose Destination
Regen Med. 2019 Mar;14(3):213-230. doi: 10.2217/rme-2018-0161. Epub 2019 Feb 14.

Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial.

Author information

1
School of Biomedical Sciences, Charles Sturt University, NSW, Australia.
2
Melbourne Stem Cell Centre, VIC, Australia.
3
Magellan Stem Cells, VIC, Australia.
4
Faculty of Science, Engineering & Technology, Swinburne University of Technology, VIC, Australia.
5
Monash University, VIC, Australia.
6
Melbourne School of Health Sciences, The University of Melbourne, VIC, Australia.
7
The Hudson Institute, VIC, Australia.

Abstract

Aim: To evaluate the efficacy of autologous adipose-derived mesenchymal stem cell (ADMSC) therapy on pain, function and disease modification in knee osteoarthritis. Methods: 30 participants with symptomatic knee osteoarthritis were randomized into three groups. Two treatment groups received intra-articular ADMSC therapy consisting of either a single injection (100 × 106 ADMSCs) or two injections (100 × 106 ADMSCs at baseline and 6 months). The third group served as control and continued conservative management. Results: No serious adverse events were observed. Both treatment groups receiving ADMSCs showed clinically significant pain and functional improvement at completion of follow-up at 12 months. Radiological analysis using the Magnetic Resonance Imaging Osteoarthritis Knee Score indicated modification of disease progression. Conclusion: Autologous ADMSC therapy appears to be a safe and effective therapy for knee osteoarthritis and may have the potential to prevent disease progression. Trial registration number: ACTRN12614000814673.

PMID:
30762487
DOI:
10.2217/rme-2018-0161
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center